Acadia Pharmaceuticals Inc. (ACAD)
Thursday, November 5, 2026
Key stats
Chart
Price, buy and sell signals and key levels on one chart.
Past 1Y
MA21MA180
SignalsBuyEarly buySellEarly sellTurning pointsSwing highSwing low
Up dayDown day
Thursday, November 5, 2026
Price, buy and sell signals and key levels on one chart.
Acadia Pharmaceuticals (ACAD) closed at $21.47 on Nov 4, 2026, up 4.4% on the day. The stock is up 8.8% over the past month, down 24.5% over three months, down 19.6% year to date and down 1.7% over the past year (since Nov 4, 2025). It trades 30.7% below its 52-week high of $30.96 and 16.7% above its 52-week low of $18.39. The close sits below its 50-day moving average ($23.20) and below its 200-day moving average ($23.60).
ACAD options were pricing 41% at-the-money implied volatility on Nov 2, 2026, an IV rank of 13 over the past year.
No — the Nov 4, 2026 close of $21.47 is 9.0% below the 200-day average of $23.60.
ACAD closed 30.7% below its 52-week high of $30.96.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.